No Data
pku healthcare corp. (000788.SZ) plans to distribute 0.5 yuan per share, with the ex-dividend date set for November 27th.
pku healthcare corp. (000788.SZ) announced that the proposed equity distribution for the first half of 2024 will be made to all shareholders of the company...
pku healthcare corp. (000788.SZ): Paroxetine hydrochloride enteric-coated sustained-release tablets approved.
On October 29, pku healthcare corp. (000788.SZ) announced that pku healthcare corp., ltd. has recently received the "Drug Registration Certificate" of Paroxetine Hydrochloride Enteric-coated Sustained-release Tablets approved and issued by the National Medical Products Administration. Paroxetine Hydrochloride Enteric-coated Sustained-release Tablets (referred to as "Paroxetine Enteric-coated Sustained-release Tablets") is a potent, highly selective serotonin reuptake inhibitor (SSRI) that improves depressive symptoms by increasing serotonin levels in the synaptic cleft, enhancing central serotonin neurotransmission. Currently, paroxetine has been recommended in multiple domestic and international treatment guidelines for depression.
Peking University Pharmaceuticals: Report for the third quarter of 2024
pku healthcare corp., (000788.SZ) released its performance for the first three quarters, with a net income of 0.13 billion yuan, a year-on-year increase of 182.49%.
pku healthcare corp. (000788.SZ) released the third quarter report for 2024. In the first three quarters, the company achieved revenue...
pku healthcare corp., (000788.SZ): The net income for the first three quarters was 0.13 billion yuan, a year-on-year increase of 182.49%.
Gelonghui October 25, pku healthcare corp., (000788.SZ) released its third quarter report. In the first three quarters of 2024, the company achieved revenue of 1.534 billion yuan, a decrease of 7.32% year-on-year; net income attributable to shareholders of the listed company was 0.13 billion yuan, an increase of 182.49% year-on-year; net income after deducting non-recurring gains and losses was 0.13 billion yuan, an increase of 221.85% year-on-year; basic earnings per share was 0.2187 yuan/share.
PKU Healthcare Corp. (000788.SZ): The current product focus of the healthcare manufacturing sector is on three major areas: anti-infective, analgesic, and mental health, with a focus on generic drugs.
GeLongHui on September 3rd, pku healthcare corp. (000788.SZ) stated on the investor interaction platform that the company's pharmaceutical manufacturing sector currently focuses on key products in the anti-infective, analgesic, and psychiatric sectors, with a focus on generic drugs. Among them, the anti-infective products mainly include erythromycin palmitate granules (applicable to various infectious diseases caused by gram-positive bacteria, such as tonsillitis, acute bronchitis, pneumonia, etc.), and moxifloxacin hydrochloride injection (applicable to adult (≥18 years old) upper and lower respiratory tract infections, such as: acute bacterial rhinosinusitis, acute exacerbation of chronic bronchitis, community-acquired pneumonia.
No Data
No Data